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Background: Characterization of molecular mechanisms underpinning development of pancreatic ductal
adenocarcinoma (PDAC) may lead to the identification of novel therapeutic targets and biomarkers. SgK223,
also known as Pragmin, is a pseudokinase and scaffolding protein closely related to SgK269/PEAK1. Both proteins are
implicated in oncogenic tyrosine kinase signaling, but their mechanisms and function remain poorly characterized.
Methods: Expression of SgK223 in PDAC and PDAC cell lines was characterized using gene expression microarrays, mass
spectrometry (MS)-based phosphoproteomics and Western blotting. SgK223 was overexpressed in human pancreatic
ductal epithelial (HPDE) cells via retroviral transduction, and knocked down in PDAC cells using siRNA. Cell proliferation
was determined using a colorimetric cell viability assay, and cell migration and invasion using transwells. Expression of
markers of epithelial-mesenchyme transition (EMT) was assayed by quantitative PCR. SgK223 and Stat3 signaling was
interrogated by immunoprecipitation, Western blot and gene reporter assays. The functional role of specific kinases and
Stat3 was determined using selective small molecule inhibitors.
Results: Elevated site-selective tyrosine phosphorylation of SgK223 was identified in subsets of PDAC cell lines,
and increased expression of SgK223 detected in several PDAC cell lines compared to human pancreatic ductal
epithelial (HPDE) cells and in PDACs compared to normal pancreas. Expression of SgK223 in HPDE cells at levels
comparable to those in PDAC did not alter cell proliferation but led to a more elongated morphology, enhanced
migration and invasion and induced gene expression changes characteristic of a partial EMT. While SgK223
overexpression did not affect activation of Erk or Akt, it led to increased Stat3 Tyr705 phosphorylation and
Stat3 transcriptional activity, and SgK223 and Stat3 associated in vivo. SgK223-overexpressing cells exhibited
increased JAK1 activation, and use of selective inhibitors determined that the increased Stat3 signaling driven
by SgK223 was JAK-dependent. Pharmacological inhibition of Stat3 revealed that Stat3 activation was required
for the enhanced motility and invasion of SgK223-overexpressing cells.
Conclusions: Increased expression of SgK223 occurs in PDAC, and overexpression of SgK223 in pancreatic ductal
epithelial cells promotes acquisition of a migratory and invasive phenotype through enhanced JAK1/Stat3 signaling.
This represents the first association of SgK223 with a particular human cancer, and links SgK223 with a major signaling
pathway strongly implicated in PDAC progression.
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Pancreatic ductal adenocarcinoma (PDAC) remains one
of most aggressive and lethal of human cancers. The
overall 5-year survival rate is <5 %, a statistic that has
not changed in almost 50 years [1]. Until recently, gem-
citabine was the current standard for post-operative
chemotherapy, delaying the development of recurrent
disease in some PDAC patients, with a modest improve-
ment in overall survival achieved upon combination with
the epidermal growth factor receptor (EGFR) -directed
tyrosine kinase inhibitor erlotinib [2]. However, recent
studies indicate that the addition of nab-paclitaxel to
gemcitabine can provide a significant survival benefit
[2], and the combined chemotherapeutic modality Folfir-
inox has emerged as a more effective treatment than
gemcitabine, although at the cost of significant toxicity
[2]. Further characterization of the molecular pathways
regulating PDAC development and progression may lead
to the identification of improved therapeutic strategies,
as well as biomarkers that help stratify patients for opti-
mal treatment.
Multiple lines of evidence support a role for deregu-
lated tyrosine kinase signaling in PDAC development
and progression. For example, activating KRas mutations
represent the earliest known genetic alteration in PDAC
[3], and evidence from genetically-modified mouse
models support their functional role in this malignancy
[4]. Signaling by the EGFR is required for acinar-ductal
metaplasia (ADM), an early step in PDAC progression,
as well as survival of cells in established ADM and pan-
creatic intraepithelial neoplasia lesions [5], and overex-
pression of the EGFR [6] and the related receptor
ERBB3 [7] has been detected in PDAC, with aberrant
expression being associated with poor prognosis. Alter-
ations can also occur in downstream signaling compo-
nents. For example, AKT2 gene amplification [8], and
loss of the tumour suppressor PTEN [9], occur in this
disease. Furthermore, tyrosine phosphorylation of the
transcriptional regulator and downstream target of JAK
signaling, Stat3, is enhanced in PDAC compared to
normal tissue [10], and is associated with poor outcome
in resected disease [11]. Importantly, conditional abla-
tion of Stat3 in KRas-driven mouse models of PDAC
have confirmed the importance of Stat3 signaling in
ADM [12], pancreatic intraepithelial neoplasia (panIN)
formation [12, 13] and panIN progression and PDAC
development [12, 14].
SgK223/Pragmin [15], and SgK269/PEAK1 [16] are
large, closely-related proteins that possess a kinase-like
domain at their C-termini. However, these kinase-like
domains contain substitutions in key motifs characteris-
tic of bona fide kinases, such as the DFG motif respon-
sible for Mg2+-ATP binding, where the aspartate residue
is substituted by asparagine. Since both proteins lacknucleotide binding activity based on a thermal shift assay,
they likely represent pseudokinases [17]. N-terminal to the
pseudokinase domain, both proteins contain tyrosine
phosphorylation sites that recruit specific SH2 and PTB
domain-containing effectors, indicating that SgK223 and
SgK269 undertake a scaffolding role during tyrosine kinase
signaling. For example, SgK223 binds to Csk, a negative
regulator of Src, via SgK223 Y411 [18], while SgK269
binds to Grb2 and Shc1 via Y635 and Y1188 to promote
proliferative and morphogenic signals, respectively
[19, 20]. Recent work has determined that SgK269
plays a key role during growth factor receptor signal-
ing, mediating a qualitative switch in EGFR output
from proliferative/survival signaling to promotion of
cell migration/invasion [20].
Importantly, SgK223 and SgK269 both exhibit emerging
oncogenic roles. For example, SgK223 promotes cell inva-
sion in colon carcinoma cells exhibiting high Src activity
[21], while overexpression of SgK269 promotes growth and
aberrant morphogenesis of MCF-10A mammary epithelial
cells, and is required for epithelial-to-mesenchymal transi-
tion (EMT) and anchorage-independent growth of basal
breast cancer cells [19]. In addition, SgK269 is required for
efficient tumour formation and metastasis in an orthotopic
pancreatic cancer xenograft model [22]. SgK269 is overex-
pressed in colon, pancreatic and breast cancers relative to
normal tissue [19, 22, 16], but the expression profile of
SgK223 in human malignancies is poorly characterized.
In this study we demonstrate that SgK223 exhibits
enhanced phosphorylation and/or expression in PDAC
cell lines and tumours relative to normal controls. In
addition, we identify a novel pathway linking SgK223,
Stat3 and an invasive phenotype during PDAC develop-
ment. Overall this work provides important new in-
sights into the signaling and oncogenic function of this
pseudokinase scaffold.
Results
SgK223 is overexpressed in pancreatic cancer
Mass spectrometry-based phosphoproteomic profiling
across a wide PDAC cell line panel detected differential
phosphorylation of SgK223 Y159 and Y411, suggesting
that SgK223 signaling is perturbed in this malignancy
(Fig. 1a, b) (Humphrey et al. manuscript in preparation).
Three cell lines (MiaPaca2, Panc10.05 and PL45) exhibited
relatively high and low levels of tyrosine phosphorylated
Y159 and Y411, respectively, while a larger subgroup of 8
cell lines were characterized by increased levels of phos-
phorylated Y411. These findings led us to assay total
SgK223 expression across this panel, and compare this
with non-transformed human pancreatic ductal epithelial
(HPDE) cells. Western blotting, using a custom rabbit
polyclonal antibody, revealed that SgK223 was overex-
pressed relative to HPDE cells in all pancreatic cancer cell
Fig. 1 SgK223 in pancreatic cancer. a-b Site-selective tyrosine phosphorylation of SgK223 across a PDAC cell line panel, determined through mass
spectrometry (Humphrey et al. manuscript in preparation). The heatmaps indicate relative tyrosine phosphorylation of SgK223 at (a) Y159;
and (b) Y411. c SgK223 protein expression across a panel of PDAC cell lines, determined by Western blotting. SgK223 protein expression in
the non-transformed pancreatic cell line, HPDE, and an overexpression cell line model utilising HPDE cells are also shown in the same immunoblot.
d SgK223 is overexpressed in PDAC compared to normal pancreas. The box plot indicates SgK223 mRNA expression in PDAC versus normal pancreatic
tissue from the same patient (6 cancer specimens and 6 normal controls were analysed). Boxes represent the interquartile range (IQR) between the
75th percentile and the 25th percentile (Q3 - Q1), and the 50th percentile (median; Q2) is represented as the line within the boxes. Error bars were
calculated as Q1 - 1.5 (IQR) and Q3 + 1.5 (IQR). ***indicates significance with a P-value < 0.0005
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was the overexpression of SgK223 in the cell lines AsPC-1
and BxPC-3, members of the cell line subgroup character-
ized by high levels of Y411 (Fig. 1c). In order to determine
whether SgK223 is overexpressed in primary PDAC, we
analysed our own gene expression data for PDAC speci-
mens and macro- and microscopically normal-appearing
pancreatic tissue from the same patients [23]. This re-
vealed a marked increase in SgK223 expression in PDACversus normal controls (Fig. 1d). Thus data from cell line
models and human tissue specimens are suggestive of
a role for SgK223 in PDAC development and/or
progression.
Overexpressing SgK223 in HPDE cells increases cell
migration and invasion
In order to characterize the functional role of SgK223 in
pancreatic cancer, we overexpressed this protein in
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coding rat SgK223 [15]. This led to an expression level
comparable to that of AsPC-1 and BxPC-3 pancreatic
cancer cells (Fig. 1c). Phosphoproteomic profiling was
undertaken to characterize site-selective phosphorylation
of the ectopically-expressed SgK223, using BxPC-3
PDAC cells as a positive control. Tyrosine phosphoryl-
ation of endogenous SgK223 at Y411 was detected in
HPDE and HPDE/SgK223 cells at a comparable level,
and at approximately 4-fold higher levels in BxPC-3
cells. In addition, compared with the phosphorylation of
endogenous Y411 in HPDEs, a slightly higher level of
tyrosine phosphorylation of Y391, the rat equivalent of
Y411, was detected in the HPDE/SgK223 cells.Fig. 2 SgK223 overexpression in HPDE cells enhances cell migration and invasi
microscope images of HPDE cells containing either: (a) the vector-control; or (b
cells (cells with lengths double their width) in the vector-control and the SgK22
mean (SEM). **indicates significance with a P-value < 0.005. d SgK223 does not
assay was used to quantify the number of cells, over time. Graph shows
and SgK223-overexpressing (grey) HPDE, cell lines. Data points represen
Data are expressed relative to the vector control, which is arbitrarily set
**indicates significance with a P-value < 0.005. f Relative cell invasion, data are re
histogram indicates relative fold-difference in transcript levels of 6 genes with si
the vector-control, cell linePhosphorylation of rat Y146, equivalent to human Y159,
was not detected (data not shown). Therefore, in the
context of SgK223 phosphorylation, HPDE/SgK223 cells
most closely model the subset of PDAC lines with high
phosphorylation of Y411 and low/undetectable phos-
phorylation of Y159 (eg Capan-1, SW1990, Fig. 1a, b).
SgK223 overexpression altered the morphology of
HPDE cells, resulting in an elongated and more refractile
mesenchymal-like phenotype (Fig. 2a–c), but did not
affect anchorage-dependent cellular proliferation (Fig. 2d).
To determine whether SgK223 contributed to a mo-
tile and invasive phenotype, transwell assays were
undertaken. SgK223 overexpression significantly in-
creased cellular migration (Fig. 2e), and to a greateron. SgK223 alters the morphology of HPDE cells grown in monolayer. Light
) the SgK223-expression construct. c The relative percentage of elongated
3-overexpression cell lines. Data represent mean and the standard error of
affect the proliferation rates of HPDE cells grown in monolayer. The MTS
the relative proliferation rates between the vector-control (black)
t mean and SEM at different time points. (E) Relative cell migration.
at 1.0. Bars represent SEM of three independent experiments,
presented as in (e). g Expression analysis on EMT-associated genes. The
gnificant changes in expression in the SgK223-overexpressing, relative to
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quisition of a mesenchymal morphology and increased
motility and invasiveness are suggestive of epithelial-to-
mesenchymal transition (EMT), we characterized the
expression of 84 EMT-related genes using a BD Bio-
science RT2 Profiler™ PCR Array. Of the 21 genes on
the array that are normally downregulated during EMT,
none showed significant change. Of the 63 genes on the
array that are normally upregulated during EMT, 6
showed a significant change, and the majority of these
(5/6) increased in expression (Fig. 2g). The latter in-
cluded TGFB1 and MMP2. These findings indicate that
SgK223 overexpression induces a partial EMT.
The impact of SgK223 on downstream signaling
pathways
Next, we sought to determine how SgK223 elicits these
biological effects by characterizing its impact on knownFig. 3 The effect of SgK223 overexpression on specific signaling pathways.
undertaken as indicated. Phospho-Erk and -Akt (T308) signals were qua
expressed relative to the value for control cells, which was arbitrarily se
independent experiments. b SgK223 enhances Stat3 tyrosine phosphorylation
**indicates significance with a P-value < 0.005. c SgK223 enhances Stat3 transc
which was arbitrarily set at 1.0. The histograms represent the mean +/− the S
P-value < 0.005. d SgK223 knockdown in AsPC-1 PDAC cells decreases Stat3 a
individual siRNAs directed against SgK223, cell lysates were prepared and Wes
(−) or SgK223-overexpressing (+) HPDE cells were subject to immunoprecipita
control). IPs or total cell lysates before IP were Western blotted as indicated. T
exposure, respectivelydownstream signaling pathways. While the related
SgK269 modulates signaling via the focal adhesion pro-
teins p130Cas and paxillin [16], phosphorylation of
p130Cas (on Y249) and paxillin (on Y31) was similar in
control and SgK223-overexpressing cells (data not
shown). In addition, activation of Erk and Akt was simi-
lar in control and SgK223-overexpressing cells (Fig. 3a).
However, Stat3 tyrosine phosphorylation was enhanced
approximately 3-fold (Fig. 3b). In order to determine
whether this was accompanied by an increase in Stat3
transcriptional activity, we undertook reporter assays
(Fig. 3c). Indeed, a corresponding increase in expres-
sion from a Stat3 reporter construct was observed in
SgK223-overexpressing cells. Additionally, knocking
down SgK223 in AsPC-1 cells using several independ-
ent siRNAs decreased Stat3 tyrosine phosphorylation
(Fig. 3d), demonstrating that endogenous high levels of
SgK223 in PDAC cells promote Stat3 activation. Sincea SgK223 does not affect activation of Erk or Akt. Western blots were
ntitated by densitometry and normalized for total expression, and
t at 1.0. The histograms represent the mean +/− the SE from three
(pY705). Data are normalized and expressed as in the previous panel.
riptional activity. Data are expressed relative to the value for control cells,
E from three independent experiments. ** indicates significance with a
ctivation. Two days following transfection using non-targeting (NT) or
tern blotted as indicated. e SgK223 and Stat3 associate in vivo. Control
tion (IP) using Stat3 antibodies, or corresponding mouse IgG (negative
he upper and lower panel of the Stat3 blot represent a short and long
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duction [18], we determined whether SgK223 and Stat3
associate. Indeed, SgK223 co-immunoprecipitated with
Stat3 (Fig. 3e).
SgK223 signals via JAK1 to enhance STAT3 activation
Next, we set out to determine how SgK223 enhances
Stat3 signaling. Known Stat3 kinases include Src fam-
ily kinases, the EGFR, and the JAKs. While total levels
of Src were similar in the SgK223-overexpressing and
vector control cells (Fig. 4a), phosphorylation of Src
Y416 (Y419 in human Src) on the activation loop was
significantly lower in the former cell type, while phos-
phorylation on the negative regulatory site Y527 (Y530
in human Src) was enhanced. Consistent with these
observations, expression of Csk, which phosphorylates
Src on Y530, was significantly higher upon SgK223
overexpression (Fig. 4a). In addition, treatment of
HPDE cells overexpressing SgK223 with the selective
Src inhibitor saracatinib did not affect Stat3 phosphor-
ylation (Fig. 4b). These data rule out SFKs as the
mediators of enhanced Stat3 phosphorylation in
SgK223-overexpressing cells.
With regard to EGFR signaling, SgK223 overexpres-
sion increased phosphorylation of the EGFR on Y1068
and decreased Grb2 levels (Fig. 5a). These data were of
interest because Y1068 represents a binding site for
both Stat3 and Grb2 [24], so these changes may lead to
enhanced EGFR signaling through Stat3. Furthermore,
SgK223 also increased phosphorylation of the EGFR on
Y845, Y1045, Y1148 and Y1173 (Fig. 5b). However,
treatment of the SgK223-overexpressing cells with the
selective EGFR tyrosine kinase inhibitor erlotinib did
not affect Stat3 activation, despite clear inhibition of EGFRFig. 4 Enhanced Stat3 activation in SgK223-overexpressing cells is not med
expression and decreases Src activity. Data are normalized and expressed a
***indicates significance with a P-value < 0.0005. b The Src inhibitor SaracatY1068 phosphorylation (Fig. 5c), indicating that the
enhanced Stat3 tyrosine phosphorylation in SgK223-
overexpressing cells was not mediated by the EGFR.
Next, we characterized the role of the JAKs. Western
blotting with appropriate phosphospecific antibodies
revealed that JAK1 activity was significantly enhanced
upon SgK223 overexpression, while JAK2 and TYK2
activities remained unchanged (Fig. 6a). In addition,
treatment of the SgK223-overexpressing cells with the
selective JAK inhibitor AG490 led to a dose-dependent
reduction of JAK1 and Stat3 phosphorylation, identify-
ing JAK1 as the likely upstream Stat3 kinase in these
cells (Fig. 6b). The role of the JAKs in Stat3 phosphor-
ylation was confirmed using the different selective JAK
inhibitor CP690550 (Fig. 6c). Of note, although we
were able to co-immunoprecipitate Stat3 with SgK223
(Fig. 3e), we could not detect association of JAK1 with
SgK223 via this approach.
Since signaling by IL-6 via the common signal transdu-
cing component of the IL6 cytokine receptor family, gp130,
represents a key mechanism for activation of JAK/Stat sig-
naling, we assayed the status of this pathway in our model
system. A commercial antibody array was used to assay the
levels of 36 different cytokines in cell culture supernatants
derived from control or SgK223-overexpressing cells. While
IL-6 could not be detected in supernatants from either cell
pool, expression of several other cytokines, including
G-CSF and IL-1α, was detectable but not altered upon
SgK223 overexpression (data not shown). In addition,
expression of gp130, as determined by Western blotting,
was similar in the two cell pools (data not shown). There-
fore, enhanced JAK1 activation upon SgK223 overexpres-
sion does not reflect increased IL-6 production or gp130
expression.iated via Src. a Overexpression of SgK223 in HPDE cells increases Csk
s in the previous figures. *indicates significance with a P-value < 0.05,
inib does not affect Stat3 expression or activation
Fig. 5 SgK223 and EGFR signaling. a Effect of SgK223 overexpression on EGFR Y1068 phosphorylation and Grb2 expression. b Effect of SgK223
overexpression on additional EGFR tyrosine phosphorylation sites. Data are normalized and expressed as in the previous figs. c The EGFR inhibitor,
erlotinib, does not affect Stat3 phosphorylation in SgK223-overexpressing cells
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To determine the functional role of Stat3 downstream of
SgK223, we utilized the small molecule Stat3 inhibitor
STATTIC [25]. Treatment of the SgK223-overexpressing
cells with STATTIC markedly reduced Stat3 phosphoryl-
ation (Fig. 7a) as well as cell migration (Fig. 7b) and in-
vasion (Fig. 7c). Thus Stat3 activation is required for the
enhanced migratory and invasive phenotype of SgK223-
overexpressing pancreatic ductal epithelial cells.
Discussion
Several studies have implicated Stat3 activation in PDAC
development and progression [12, 11, 13, 14, 10]. Previ-
ous reports indicated that the major signaling pathway
leading to activation of Stat3 in PDAC is cytokine-
induced tyrosine phosphorylation of the signaling co-
receptor gp130 and JAK activation [12], and this can
occur in a cell autonomous fashion [12, 13], as well as
via a cell non-autonomous mechanism involving IL-6
production by infiltrating myeloid cells [14]. Increased
production and/or exposure to cytokines, and upregula-
tion of gp130, represent identified mechanisms for the
enhanced activation of Stat3 detected in PDAC versus
normal tissue [12–14]. Our identification of increased
expression of SgK223 in PDAC versus normal tissue,
and demonstration that SgK223 is sufficient to increase
Stat3 activation in HPDE cells and is required for Stat3
phosphorylation in AsPC-1 PDAC cells, now identifyaberrant expression of this pseudokinase as an additional
mechanism for enhancement of Stat3 signaling in
PDAC. While all details of SgK223 action on this path-
way have yet to be resolved, our work identifies certain
key aspects. First, since JAK1 activation was enhanced in
SgK223-overexpressing cells, and selective JAK inhibi-
tors could normalize Stat3 phosphorylation, SgK223
must act upstream of JAK1 to amplify Stat3 signaling.
Second, increased production of IL6, and altered expres-
sion of gp130, do not appear to be involved. Third, since
SgK223 associates with Stat3, this implicates the scaf-
folding function of SgK223 in regulation of Stat3 phos-
phorylation, although SgK223 does not itself ‘bridge’
Stat3 and JAK1. The possibility that SgK223 complexes
both gp130 and Stat3, or alters the activity of particular
protein tyrosine phosphatases, such as TC-PTP [26],
towards Stat3, is currently under investigation. Whatever
the mechanism, the phosphorylated Stat3 generated in
SgK223-overexpressing cells is competent for nuclear
translocation and transcriptional activation of target
genes, as confirmed by our reporter assays.
Reflecting their relationship as paralogues, SgK223 and
SgK269 exhibit similarities and differences in function
and signal output. Both proteins regulate cell morph-
ology, promoting a more elongated phenotype [19, 18]
and a partial EMT [19]. With regard to the latter
process, it is noteworthy that increased expression of
either protein led to enhanced expression of MITF, a
Fig. 6 SgK223 signals via JAK1/Stat3. a Overexpression of SgK223 enhances JAK1 activation. Data are normalized and expressed as in Fig. 3.
*indicates significance with a P-value < 0.05. b-c Activation of Stat3 in SgK223-overexpressing cells is JAK-dependent. b AG490 or c CP690550
were applied for 2 h prior to cell lysis. Cell lysates were then Western blotted as indicated
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migration/invasion and proliferation in melanoma cells,
and particular TGFβ family members, that are known to
promote acquisition of a mesenchymal phenotype (Fig. 2)
[19, 27, 28]. In addition, both SgK223 and SgK269
modulate the tyrosine phosphorylation of specific erbB
receptors. The Klemke group [22] demonstrated that
SgK269 associated with erbB2, and SgK269 knockdownFig. 7 Promotion of cell migration and invasion by SgK223 is Stat3-dependent.
cells were treated with Stat3 inhibitor, STATTIC, at the indicated concentrations
b-c Effect of STATTIC on cell migration and invasion. Treatment of SgK223-overe
(c) to levels comparable to that of untreated control cells. Cell migration and inv
which is arbitrarily set at 1.0. Data represent the mean +/− SEM of three indepedecreased phosphorylation of this receptor on specific
sites, while we observed enhanced EGFR tyrosine phos-
phorylation upon SgK223 overexpression. However,
while SgK269 enhanced site-selective tyrosine phosphor-
ylation of paxillin and p130Cas [16], this direct impact
on focal adhesion signaling was not observed in our
SgK223 overexpression model. In addition, while
SgK269 increases Erk activation [19, 16], this was nota Inhibition of Stat3 activation using STATTIC. SgK223-overexpressing HPDE
for 2 h prior to cell lysis. Cell lysates were then Western blotted as indicated.
xpressing cells with STATTIC (2.5 μM) reduced migration (b) and invasion
asion are expressed relative to the value for untreated control HPDE cells,
ndent experiments. *indicates significance with a P-value < 0.05
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This likely reflects the absence of a direct Grb2 binding
site in SgK223, while SgK269 recruits this adaptor via
Y635 [19].
Interestingly, previous studies reported positive regula-
tion of Src by SgK223 and SgK269 [22, 18]. In the case
of the former pseudokinase, this reflected sequestration
of Csk in the cytosol by SgK223, leading to activation of
plasma membrane-localized Src [18]. However, this was
demonstrated using transient expression assays in gastric
epithelial cells, and in our HPDE cells stably expressing
SgK223, Src activity was decreased, likely reflecting a
robust increase in Csk expression in the SgK223-
overexpressing cells, which may represent a negative
feedback mechanism. Taking these data and those from
the Hatakeyama group in combination, the effect of
SgK223 on Src may be context-dependent, and vary ac-
cording to the relative abundance of Src and its regula-
tors in specific subcellular localizations.
An additional conserved feature of SgK223 and
SgK269 is their ability to enhance activation of Stat3
([19], this paper). In the case of SgK223, we utilized the
Stat3 inhibitor Stattic to demonstrate that a key role for
SgK223-induced Stat3 signaling is enhanced cellular
migration and invasion. The cellular function of Stat3
signaling downstream of SgK269 has yet to be defined,
although mutation of Y635 to phenylalanine, which
abrogates SgK269-mediated activation of both Erk and
Stat3, negatively impacts upon both proliferation in 3D
culture and cellular invasion [19]. Consequently, it
appears likely that Stat3 represents a common effector
utilized by both pseudokinases to drive acquisition of a
migratory and invasive phenotype. This highlights an
important oncogenic role for both SgK223 and SgK269
in PDAC, given that both are overexpressed in this
malignancy (this paper, [22]) and the critical role played
by Stat3 in PDAC development [12–14] and metastasis
[29]. In addition, the strong links between these pseudo-
kinases and Stat3 signaling indicate that SgK223 and
SgK269 represent candidate biomarkers for responsive-
ness to targeted therapies directed at the JAK/Stat3
pathway.
Conclusions
Accumulating evidence indicates that pseudokinases play
key roles in regulating intracellular signaling pathways
by functioning as allosteric regulators or scaffolds [30, 20].
The signaling potential of pseudokinases is also reflected in
the growing number of these proteins implicated in human
disease, including cancer [31]. In this manuscript, we
extend these findings by demonstrating a novel role for the
pseudokinase SgK223 in PDAC. Specifically, SgK223 is
overexpressed in PDAC relative to normal pancreatic tissue
and promotes acquisition of a migratory and invasivephenotype in pancreatic ductal epithelial cells through
enhanced JAK1/Stat3 signaling. This represents the first
association of SgK223 with a particular human cancer, and
links SgK223 with a major signaling pathway strongly
implicated in PDAC progression.
Materials and methods
Plasmids
The retroviral expression vector pBabe-puro/myc-Pragmin
was a kind gift from Serge Roche, Centre for Biochemical
and Macromolecular Research (CRBM), Montpellier
Cedex, France [21], and was previously generated in the
laboratory led by Manabu Negishi, Kyoto University, Kyoto,
Japan [15].
Cell culture and generation of stable cell lines
HPDE cells stably expressing the murine ecotropic
receptor were maintained in Keratinocyte Serum-Free
Media (K-SFM), supplemented with 2.5 μg human
recombinant EGF and 25 mg bovine pituitary extract per
litre (Gibco®, Life Technologies, USA). All pancreatic
cancer cell lines were obtained from the American Type
Culture Collection (ATCC, USA) and were maintained
according to ATCC guidelines. The packaging cell line
PlatE was used for retrovirus production, and HPDE
cells were infected with retrovirus using the method pre-
viously described [32]. Puromycin (Sigma-Aldrich, USA)
was used to select for pBabe-puro-positive HPDE cells
at a concentration of 200 ng/ml for 14 days.
Tyrosine phosphorylation profiling
Global tyrosine phosphorylation profiling was under-
taken by immunoaffinity purification and liquid
chromatography-tandem mass spectrometry, as previously
described [33, 34], using heavy amino acid-labelled syn-
thetic phosphotyrosine-containing peptides for data
normalization [35].
Antibodies, inhibitors and siRNA treatment
All antibodies were from Cell Signaling Technology,
except Actin (Santa Cruz, USA) and SgK223. The
affinity-purified rabbit antibody selective for SgK223
was generated by Cambridge Research Biochemicals Ltd.
by standard procedures. [C]-PTDHSNSTTWHRLHPTD
GS-amide was used as the antigen. The following inhibitors
were used in this study: Erlotinib hydrochloride (Symansis,
USA); AG490, CP690550 (Tocris Bioscience, USA);
AZD0530 (saracatinib) (a kind gift from Ian Steet, Cancer
Therapeutics CRC, Vic, Australia); and STAT3 Inhibitor V,
STATTIC (Calbiochem, Merck Millipore, Germany). Cells
were treated with inhibitors for 2 h at the indicated concen-
trations prior to cell lysis for immunoblot analysis. The
Universal Negative Control #1 (SIC001) and the SgK223-
selective siRNAs (SASI_Hs02_0031603-3 to −6) were
Tactacan et al. Molecular Cancer  (2015) 14:139 Page 10 of 11obtained from Sigma-Aldrich. siRNA was applied to cells
(final concentration, 5 nM) using Lipofectamine 2000 (Invi-
trogen, USA) transfection reagent using the method previ-
ously described [32].
Immunoprecipitation and immunoblotting
Cell lysates for immunoprecipitation and immunoblot-
ting were prepared using normal lysis buffer [36]. Both
Myc-Tag (#2272, Cell Signaling Technology) and SgK223
(Cambridge Research Biochemicals Ltd) antibodies were
used to confirm expression from the pBabe-puro/myc-
Pragmin plasmid in HPDE cells.
Cell proliferation, migration and invasion assays
Cell proliferation assays were conducted using MTS
reagent as previously described [32]. For migration and
invasion assays, HPDE cells were starved for 24 h with
K-SFM without supplements, prior to starting the assays.
Assays were performed using cell culture inserts with
8 μM pore size PET filters designed for 24-well plates,
uncoated (BD Falcon™ Cell Culture Inserts; BD Biosciences)
and coated in Matrigel (BD Biocoat™ Growth Factor
Reduced MATRIGEL™ Invasion Chamber; BD Biosciences),
for assaying migration and invasion, respectively. For inva-
sion assays, the Matrigel was rehydrated with K-SFM with-
out supplements, for 2 h at 37 °C in 5 % CO2, prior to cell
seeding. The lower compartment of each well was filled
with 0.75 ml of K-SFM supplemented with EGF and bovine
pituitary extract. The upper compartment, within the
inserts, was filled with 0.5 ml of resuspended cell solution
(2.5 × 104 cells/0.5 ml of K-SFM without supplements).
Cells were subsequently incubated for 24 h at 37 °C in 5 %
CO2 to allow migration/invasion through the filter, after
which, remaining cells in the upper compartment were re-
moved by swabbing with a cotton tip. The filter from the
insert was subsequently stained using Diff Quick solution
(Lab Aids Pty. Ltd., Australia). Stained cells that had mi-
grated/invaded through to the underside of the filter were
subsequently photographed and quantified using ImageJ
software (version 10.2).
Quantitative RT-PCR analysis of EMT genes
The RNeasy Kit (Qiagen) was used to extract RNA and
reverse transcription was conducted with the RT2 First
Strand Kit (Qiagen). The RT2 Profiler PCR Array for
Human EMT (PAHS-0902E-4; Qiagen) was used for
gene expression profiling and quantitative RT-PCR was
carried out on an Applied Biosystems ABI 7900 qPCR
machine. Data were analyzed using the 2ΔΔCt method.
STAT3 reporter assay
The pGL4.23/APRE-luc construct used in this assay was
a kind gift from Matthias Ernst (Walter and Eliza Hall
Institute of Medical Research, Melbourne, VIC, Australia).The construct was made by inserting 8 × APRE sites into a
firefly luciferase pGL4.23 (Promega, USA) vector, using a
method modified from Takeda, T. et al. (1994) [37]. A
renilla luciferase pRL-TK (Promega) vector was used as the
corresponding co-transfection control. Untransfected cells
were used as negative controls, while IL-6-treated cells
were used as positive controls. Positive control cells were
treated with IL-6 (100 ng/ml) for 6 h prior to the measure-
ment of the assay on day three. On day one, HPDE_pBabe-
puro and HPDE_pBabe-puro/myc-Pragmin cells were
seeded, in replicate, at 2 × 105 cells/well, in a 24-well plate.
On day two, 2 μg of pGL4.23/APRE-luc (firefly) and 0.2 μg
of pRL-TK (renilla) vectors were co-transfected into the
cells using Lipofectamine 2000 (Invitrogen) according to
the transfection reagent manufacturer instructions. On day
three, cells were lysed, and the luminescence from firefly
and renilla luciferase activity was measured using reagents
from the Dual-Luciferase® Reporter Assay System (Pro-
mega) and read on a FLUOstar OPTIMA (BMG Labtech,
Germany).
Statistical tests
These were by standard t-tests, unless otherwise indicated.
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